ArticleJournal for immunotherapy of cancer2023

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Markus Joerger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.